#liver disease

Phase III trial results reported in the New England Journal of Medicine showed roughly one in five chronic hepatitis B patients achieved a functional cure after 24 weeks of bepirovirsen.

A clinical trial suggests macrophage-based cell therapy could meaningfully improve four-year transplant-free survival for patients with advanced cirrhosis, offering a potential alternative to liver transplantation for a病

Intercept Pharmaceuticals’ next-generation FXR agonist INT-787 failed a Phase 2 study, according to the supplied report, deepening pressure on a drug developer already facing another clinical setback.

A University of Michigan study points to a newly identified liver cell type that may offer clues to severe liver disease and future treatment strategies.

A Julius Maximilian University of Wurzburg study reports that a rare type of T cell can trigger signaling that amplifies inflammation and contributes to liver fibrosis.

Researchers are developing a blood test that uses machine learning to analyze circulating DNA linked to liver scarring, with the goal of identifying disease earlier and reducing progression to liver cancer.